More importantly this show that Europe look at CE Mark (which was a major concern) to use the medical device, there's no doubt the 1st US clinical trial was stuff up by management but the 2nd US clinical trial were 33% of the time the 2 respiratory doctors at one of the most prodigious hospital couldn't even agree indicate how subjective respiratory disease diagnosis will always be if ResAppDx isn't used.
RAP Price at posting:
9.4¢ Sentiment: Buy Disclosure: Held